Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation

网站地图 | English | 公务邮箱

About the library

Background
History
Leadership
Organization

Opening Hours
Collections
Help Via Email

Electronic Information Resources

Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation

详细信息查看全文

作者：Armin Ghobadi ; MD^a ; ^{aghobadi@wustl.edu" class="auth_mail" title="E-mail the corresponding author} ; Jaebok Choi ; PhD^a ; Mark A. Fiala ; BS ; CCRP^a ; Theresa Fletcher ; MS^a ; Jingxia Liu ; PhD^b ; Linda G. Eissenberg ; PhD^a ; Camille Abboud ; MD^a ; Amanda Cashen ; MD^a ; Ravi Vij ; MD^a ; Mark A. Schroeder ; MD^a ; Iskra Pusic ; MD^a ; Keith Stockerl-Goldstein ; MD^a ; Meagan Jacoby ; MD ; PhD^a ; Geoffrey Uy ; MD^a ; John DiPersio ; MD ; PhD^a ; Peter Westervelt ; MD ; PhD^a
关键词：Allogeneic stem cell transplantation ; Acute myeloid leukemia ; Donor lymphocyte infusion ; Azacitidine ; Graft versus host disease
刊名：Leukemia Research
出版年：2016
出版时间：October 2016
年：2016
卷：49
期：Complete
页码：1-6
全文大小：1217 K

文摘

•: Azacitidine (AzaC) on days 4, 6, 8, and 10 post DLI is safe.
•: AzaC early post DLI can potentially prevent GVHD.
•: The effect of AzaC post DLI on GVHD and GVL should be studied in a larger study.

NGLC 2004-2010.National Geological Library of China All Rights Reserved.
Add:29 Xueyuan Rd,Haidian District,Beijing,PRC. Mail Add: 8324 mailbox 100083
For exchange or info please contact us via email.